Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports.

Siskind E, Bhaskaran M, Boctor F, Shah K, Molmenti E.

Int J Angiol. 2012 Jun;21(2):107-10. doi: 10.1055/s-0032-1315622.

2.

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE.

Transplantation. 2000 Sep 27;70(6):887-95.

PMID:
11014642
3.

Acute antibody-mediated rejection in paediatric renal transplant recipients.

Kranz B, Kelsch R, Kuwertz-Bröking E, Bröcker V, Wolters HH, Konrad M.

Pediatr Nephrol. 2011 Jul;26(7):1149-56. doi: 10.1007/s00467-011-1864-3.

PMID:
21461632
4.

Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.

Jirasiritham S, Khunprakant R, Techawathanawanna N, Jirasiritham S, Mavichak V.

Transplant Proc. 2010 Apr;42(3):987-9. doi: 10.1016/j.transproceed.2010.03.018.

PMID:
20430222
5.
6.

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C.

Am J Transplant. 2009 May;9(5):1099-107. doi: 10.1111/j.1600-6143.2009.02591.x.

7.
8.

Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.

Stuckey LJ, Kamoun M, Chan KM.

Ann Pharmacother. 2012 Jan;46(1):e2. doi: 10.1345/aph.1Q509.

PMID:
22202499
9.

Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients.

Luke PP, Scantlebury VP, Jordan ML, Vivas CA, Hakala TR, Jain A, Somani A, Fedorek S, Randhawa P, Shapiro R.

Transplantation. 2001 Aug 15;72(3):419-22.

PMID:
11502969
10.

Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.

Ibernón M, Gil-Vernet S, Carrera M, Serón D, Moreso F, Bestard O, Cruzado JM, Grinyó JM.

Transplant Proc. 2005 Nov;37(9):3743-5.

PMID:
16386524
11.

Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.

Sureshkumar KK, Hussain SM, Marcus RJ, Ko TY, Khan AS, Tom K, Vivas CA, Parris G, Jasnosz KM, Thai NL.

Clin Nephrol. 2012 Mar;77(3):246-53. Review.

PMID:
22377258
12.

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection.

Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR.

Transplantation. 2003 May 15;75(9):1490-5.

PMID:
12792502
13.

Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience.

Padmanabhan A, Ratner LE, Jhang JS, Duong JK, Markowitz GS, Vasilescu ER, Crew RJ, Schwartz J.

Transplantation. 2009 Jun 27;87(12):1889-96. doi: 10.1097/TP.0b013e3181a76ae1.

PMID:
19543070
14.

Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.

Lehrich RW, Rocha PN, Reinsmoen N, Greenberg A, Butterly DW, Howell DN, Smith SR.

Hum Immunol. 2005 Apr;66(4):350-8.

PMID:
15866697
15.

Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.

Tanimine N, Ide K, Yamashita M, Tanaka Y, Igarashi Y, Banshodani M, Tazawa H, Basnet NB, Doskali M, Onoe T, Tashiro H, Ohdan H.

Transplant Proc. 2011 Jul-Aug;43(6):2411-4. doi: 10.1016/j.transproceed.2011.05.039.

PMID:
21839279
16.

Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection.

White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, Tellis V.

Transplantation. 2004 Sep 15;78(5):772-4.

PMID:
15371687
17.

Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis.

Bryan CF, McDonald SB, Luger AM, Shield CF, Winklhofer FT, Michael Borkon A, Warady BA, Aeder MI, Murillo D.

Clin Transplant. 2006 Sep-Oct;20(5):563-70.

PMID:
16968481
18.
19.

Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.

Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O.

Ther Apher Dial. 2009 Apr;13(2):108-12. doi: 10.1111/j.1744-9987.2009.00664.x.

PMID:
19379149
20.

Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up.

Lai Q, Pretagostini R, Gozzer M, Cinti P, Meo D, Vita F, Shafii Bafti M, Poli L, Novelli G, Rossi M, Girelli G, Berloco PB.

Transplant Proc. 2011 May;43(4):1039-41. doi: 10.1016/j.transproceed.2011.03.023.

PMID:
21620047
Items per page

Supplemental Content

Support Center